Unit
Brustzentrum St.Gallen
BZ · Dept. IV
Ixabepilon bei lokal fortgeschrittenem oder metastasiertem Mammakarzinom: Neue Behandlungsoptionen nach Taxanen und Anthrazyklinen
Templeton A, Thürlimann B, Jörger M. Ixabepilon bei lokal fortgeschrittenem oder metastasiertem Mammakarzinom: Neue Behandlungsoptionen nach Taxanen und Anthrazyklinen. Schweizer Krebsbulletin 2009:114-117.
Jun 18, 2009Ixabepilon bei lokal fortgeschrittenem oder metastasiertem Mammakarzinom: Neue Behandlungsoptionen nach Taxanen und Anthrazyklinen
Jun 18, 2009Schweizer Krebsbulletin 2009:114-117
Templeton Arnoud, Thürlimann Beat, Jörger Markus
Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis
Harter P, Loibl S, Meier W, Huober J, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emons G, Burges A, Hasenburg A, Hahmann M, Lueck H, Poelcher M, Wimberger P, Ortmann O, Canzler U, Richter B, Wagner U, du Bois A. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Annals of surgical oncology 2009; 16:1324-30.
May 1, 2009Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis
May 1, 2009Annals of surgical oncology 2009; 16:1324-30
Harter P, Loibl S, Meier W, Huober Jens, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emons G, Burges A, Hasenburg A, Hahmann M, Lueck H J, Poelcher M, Wimberger P, Ortmann O, Canzler U, Richter B, Wagner U, du Bois A
Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer
Winder T, de Vries A, Wenzl E, Drexel H, Knauer M, Hartmann B, Dirschmid K, Rhomberg S, Mündlein A, Lang A. Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep 2009; 21:1283-7.
May 1, 2009Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer
May 1, 2009Oncol Rep 2009; 21:1283-7
Winder Thomas, de Vries Alexander, Wenzl Etienne, Drexel Heinz, Knauer Michael, Hartmann Bernd L, Dirschmid Klaus, Rhomberg Simone, Mündlein Axel, Lang Alois
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer
Chan S, Frimodt-Moller B, Vaury A, Carrasco E, Jones A, Harrison M, Antón A, Mayordomo J, Kreienberg R, du Bois A, Llombart A, Lluch A, Schneeweiss A, Tubiana-Hulin M, Delozier T, Huober J, Romieu G, Fumoleau P. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27:1753-60.
Apr 10, 2009Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer
Apr 10, 2009Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27:1753-60
Chan Stephen, Frimodt-Moller Bente, Vaury A Thareau, Carrasco Eva, Jones Alison, Harrison Mark, Antón Antonio, Mayordomo Jose Ignacio, Kreienberg Rolf, du Bois Andreas, Llombart Antonio, Lluch Ana, Schneeweiss Andreas, Tubiana-Hulin Michele, Delozier Thierry, Huober Jens, Romieu Gilles, Fumoleau Pierre
Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
Ribi K, Pestalozzi B, Lombriser N, Borner M, von Moos R, Moosmann P, Hess V, Roth A, Honegger H, Schuller J, Köberle D, Ruhstaller T. Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009; 17:1109-1116.
Feb 7, 2009Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
Feb 7, 2009Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009; 17:1109-1116
Ribi Karin, Pestalozzi Bernhard, Lombriser Norbert, Borner Markus, von Moos Roger, Moosmann Peter, Hess Viviane, Roth Arnaud, Honegger Hanspeter, Schuller Jan C, Köberle Dieter, Ruhstaller Thomas
Neue Behandlungsoptionen beim metatstasierten Kolorektalkarzinom
Baumann M, Weder P, Köberle D. Neue Behandlungsoptionen beim metatstasierten Kolorektalkarzinom - Bewertung der aktuellen Studeienresultate und Konsequenzen. Schweizer Zeitschrift für Onkologie 2009:14-19.
Jan 1, 2009Neue Behandlungsoptionen beim metatstasierten Kolorektalkarzinom
Jan 1, 2009Schweizer Zeitschrift für Onkologie 2009:14-19
Baumann Michael, Weder Patrik, Köberle Dieter
Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study
Ruhstaller T, Böhme C, Hess D, Hoefliger M, Mueller U, Köberle D, Spaeti B, Glaus A, Ribi K, Rufibach K, von Moos R, Thürlimann B. Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. Oncology 2009; 76:142-8.
Jan 1, 2009Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study
Jan 1, 2009Oncology 2009; 76:142-8
Ruhstaller Thomas, Böhme Christel, Hess Dagmar, Hoefliger Markus, Mueller Urs, Köberle Dieter, Spaeti Bruno, Glaus Agnes, Ribi Karin, Rufibach Kaspar, von Moos Roger, Thürlimann Beat
Adenokarzinome des Oesophagus und des Magens: Vergleichende Epidemiologie mit markanten Unterschieden
Inauen R, Ruhstaller T. Adenokarzinome des Oesophagus und des Magens: Vergleichende Epidemiologie mit markanten Unterschieden. Onkologie 2009; 1:6-7.
Jan 1, 2009Adenokarzinome des Oesophagus und des Magens: Vergleichende Epidemiologie mit markanten Unterschieden
Jan 1, 2009Onkologie 2009; 1:6-7
Inauen Roman, Ruhstaller Thomas
Magen- und gastroösophageales Uebergangskarzinom: Diagnostik und Therapieoptionen des frühen bis metastasierten Tumorstadiums
Inauen R, Ruhstaller T. Magen- und gastroösophageales Uebergangskarzinom: Diagnostik und Therapieoptionen des frühen bis metastasierten Tumorstadiums. Onkologie 2009; 1:8-13.
Jan 1, 2009Magen- und gastroösophageales Uebergangskarzinom: Diagnostik und Therapieoptionen des frühen bis metastasierten Tumorstadiums
Jan 1, 2009Onkologie 2009; 1:8-13
Inauen Roman, Ruhstaller Thomas
Radiation recall dermatitis with soft tissue necrosis following pemetrexed therapy: a case report
Spirig C, Omlin A, D'Addario G, Loske K, Esenwein P, Geismar J, Ruhstaller T. Radiation recall dermatitis with soft tissue necrosis following pemetrexed therapy: a case report. J Med Case Reports 2009; 3:93.
Jan 1, 2009Radiation recall dermatitis with soft tissue necrosis following pemetrexed therapy: a case report
Jan 1, 2009J Med Case Reports 2009; 3:93
Spirig Christian, Omlin Aurelius, D'Addario Giannicola, Loske Klaus-Dieter, Esenwein Philipp, Geismar Jan Henning, Ruhstaller Thomas
St. Gallen 2009 recommendations on the treatment of early breast cancer: consensus and controversy
Jörger M, Senn H, Thürlimann B. St. Gallen 2009 recommendations on the treatment of early breast cancer: consensus and controversy. magazine of european medical oncology 2009; 2:229-231.
Jan 1, 2009St. Gallen 2009 recommendations on the treatment of early breast cancer: consensus and controversy
Jan 1, 2009magazine of european medical oncology 2009; 2:229-231
Jörger Markus, Senn H J, Thürlimann Beat
Patterns of care of breast cancer patients in Switzerland: A population based study
Ess S, Savidan A, Bouchardy C, Bordoni A, Konzelmann I, Jundt G, Probst N, Frick H, Thürlimann B. Patterns of care of breast cancer patients in Switzerland: A population based study - Advisory Board: Bachmann G, St.Gallen (Public Health), Lütolf U, Zurich (Radio Oncology), Obrist R, Sion (Medical Oncology), Rageth Ch, Zurich (Breast Surgery), Vlastos G, Geneva (Breast Surgery), Thürlimann B, St.Gallen (Medical Oncology). http://www.krebsliga-sg.ch/de/krebsregister/index.cfm 2009
Jan 1, 2009Patterns of care of breast cancer patients in Switzerland: A population based study
Jan 1, 2009http://www.krebsliga-sg.ch/de/krebsregister/index.cfm 2009
Ess S, Savidan A, Bouchardy Ch, Bordoni A, Konzelmann I, Jundt G, Probst N, Frick H, Thürlimann Beat
ASCO 2009: What's new in breast cancer therapy?
Biganzoli L, Bonnefoi H, Cardoso F, Coleman R, Thürlimann B. ASCO 2009: What's new in breast cancer therapy?. Breast Care 2009; 4:268-271.
Jan 1, 2009ASCO 2009: What's new in breast cancer therapy?
Jan 1, 2009Breast Care 2009; 4:268-271
Biganzoli L, Bonnefoi H, Cardoso F, Coleman R, Thürlimann Beat
Neue Erkenntnisse vom SABCS, Expert Discussion
Jakesz R, Dubsky P, Eidtman H, Schem C, Lang A, Thürlimann B. Neue Erkenntnisse vom SABCS, Expert Discussion. Breast Care 2009; 4:55-60.
Jan 1, 2009Neue Erkenntnisse vom SABCS, Expert Discussion
Jan 1, 2009Breast Care 2009; 4:55-60
Jakesz R, Dubsky P, Eidtman H, Schem C, Lang A, Thürlimann Beat
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93
Thürlimann B, Coates A, Castiglione-Gertsch M, Forbes J, Collins J, Colleoni M, Crivellari D, Holmberg S, Gelber R, Price K, Goldhirsch A. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 2009; 113:137-44.
Jan 1, 2009Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93
Jan 1, 2009Breast Cancer Res Treat 2009; 113:137-44
Thürlimann Beat, Coates Alan S, Castiglione-Gertsch Monica, Forbes John F, Collins John, Colleoni Marco, Crivellari Diana, Holmberg Stig B, Gelber Richard D, Price Karen N, Goldhirsch Aron
Polychemotherapy in metastatic breast cancer - pro
Huober J, Thürlimann B. Polychemotherapy in metastatic breast cancer - pro. Breast Care 2009; 4:367-372.
Jan 1, 2009Polychemotherapy in metastatic breast cancer - pro
Jan 1, 2009Breast Care 2009; 4:367-372
Huober Jens, Thürlimann Beat
Adjuvante endokrine Therapie in der Prämenopause
Huober J, Scharl T. Adjuvante endokrine Therapie in der Prämenopause - Aktuelle Empfehlungen zur Therapie primärer und fortgeschrittener Mammakarzinome. In: Kommission Mamma der AGO, vertreten durch Thomssen C (Hrsg.). 3. AuflageMünchen, Wien, New York: Zuckschwerdt Verlag, 2009. pp. 1-9.
Jan 1, 2009Adjuvante endokrine Therapie in der Prämenopause
Jan 1, 2009Zuckschwerdt Verlag
Huober Jens, Scharl T
Ovarialkarzinom
Huober J, Grischke E, Marme A. Ovarialkarzinom. In: Die Onkologie (Hrsg. Hiddemann W, Bartram C.R.). 2. AuflageHeidelberg: Springer Medizin Verlag, 2009. pp. 990-1003.
Jan 1, 2009Ovarialkarzinom
Jan 1, 2009Springer Medizin Verlag
Huober Jens, Grischke E-M, Marme A.
Interdisziplinary S2K guideline on the diagnosis and treatment of cervical carcinoma
Beckmann M, Malmann P, Blohmer J, Huober J, Weidner N. Interdisziplinary S2K guideline on the diagnosis and treatment of cervical carcinoma. J Cancer Res Clin Oncol 2009; 135:1197-1206.
Jan 1, 2009Interdisziplinary S2K guideline on the diagnosis and treatment of cervical carcinoma
Jan 1, 2009J Cancer Res Clin Oncol 2009; 135:1197-1206
Beckmann M, Malmann P, Blohmer J, Huober Jens, Weidner N
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
Pfisterer J, Arnold N, Burchardi N, Schmalfeldt B, Huober J, Harter P, Kommoss F, Bentz E, du Bois A, Hilpert F. Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009; 19:109-15.
Jan 1, 2009Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
Jan 1, 2009International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009; 19:109-15
Pfisterer Jacobus, Arnold Norbert, Burchardi Nicole, Schmalfeldt Barbara, Huober Jens, Harter Philipp, Kommoss Friedrich, Bentz Eva-Katrin, du Bois Andreas, Hilpert Felix